Similar Stories 🔰

Merck and Moderna's personalised mRNA cancer vaccine shows promising melanoma results, potentially changing how doctors prevent cancer from returning after surgery., Health, Times Now

Moderna and Merck's personalised mRNA cancer vaccine plus Keytruda cut melanoma recurrence and spread risk in a 1,137-patient Phase 3 trial, marking a major milestone for mRNA cancer treatment.

Merck and Moderna have announced that their personalised mRNA cancer vaccine, intismeran autogene, succeeded in a Phase 3 trial for high-risk melanoma when given with Keytruda.

Moderna and Merck's personalised mRNA cancer vaccine has shown positive Phase 3 results when combined with Keytruda in high-risk melanoma. The treatment reduced the risk of recurrence and distant spread, marking a significant step for personalised cancer treatment.

EXCLUSIVE

Moderna has announced it will provide its COVID vaccine for free to people without insurance, even after government money dries up.

Moderna's COVID-19 mRNA vaccine is likely to offer protection of up to a couple of years, its chief executive said on Thursday, even though more data is still needed to make a definitive assessment.

Moderna Inc said on Monday it would produce at least 600 million doses of its COVID-19 vaccine in 2021, up by 100 million doses from its previous forecast, as the United States continues to roll-out the vaccine.